NCT00645671

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery

Conditions

• Ocular Inflammation

Interventions

Type	Name	Description
DRUG	0.5% Loteprednol Etabonate Ophthalmic Ointment	1/2 inch ribbon four times a day for 14 days
DRUG	Vehicle of Loteprednol Etabonate Ophthalmic Ointment	1/2 inch ribbon four times a day for 14 days

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-03-28
• Last updated: 2015-03-24
• Results posted: 2010-09-23

Locations

1 site across 1 country: United States